Analysis Article • Aug 27
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Biotech Industry Analysis
UpdatedAug 28, 2026
DataAggregated Company Financials
Companies67
- 7D3.1%
- 3M2.6%
- 1Y-16.6%
- YTD-5.2%
Over the last 7 days, the Biotech industry has risen 3.1%, driven by gains from Innovent Biologics of 5.0%. In contrast, the industry has lost 17% in the last 12 months. Looking forward, earnings are forecast to grow by 27% annually.
Industry Valuation and Performance
Has the Hong Kong Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sat, 29 Aug 2026 | HK$988.8b | HK$107.2b | HK$6.0b | 20.3x | 164.6x | 9.2x |
| Mon, 27 Jul 2026 | HK$915.8b | HK$94.8b | -HK$4,013,081,646.94 | 25.6x | -228.2x | 9.7x |
| Wed, 24 Jun 2026 | HK$804.1b | HK$94.5b | -HK$4,629,686,758.10 | 17.5x | -173.7x | 8.5x |
| Fri, 22 May 2026 | HK$941.9b | HK$94.2b | -HK$3,916,267,163.24 | 20.8x | -240.5x | 10x |
| Sun, 19 Apr 2026 | HK$1.1t | HK$93.1b | -HK$4,258,183,300.34 | 28.6x | -269.7x | 12.3x |
| Tue, 17 Mar 2026 | HK$939.9b | HK$72.5b | -HK$12,065,601,761.66 | 50.1x | -77.9x | 13x |
| Thu, 12 Feb 2026 | HK$1.0t | HK$70.8b | -HK$14,079,997,415.21 | 37.6x | -71.5x | 14.2x |
| Sat, 10 Jan 2026 | HK$1.0t | HK$70.2b | -HK$13,864,371,989.49 | 40.7x | -74.8x | 14.8x |
| Mon, 08 Dec 2025 | HK$1.0t | HK$69.3b | -HK$12,927,092,832.44 | 41.7x | -79.5x | 14.8x |
| Wed, 05 Nov 2025 | HK$993.6b | HK$68.6b | -HK$12,787,890,226.33 | 42.9x | -77.7x | 14.5x |
| Fri, 03 Oct 2025 | HK$1.2t | HK$68.4b | -HK$12,902,452,948.18 | 58.5x | -89.2x | 16.8x |
| Sun, 31 Aug 2025 | HK$1.1t | HK$67.6b | -HK$14,862,320,409.56 | 48.2x | -71.7x | 15.8x |
| Tue, 29 Jul 2025 | HK$962.3b | HK$63.7b | -HK$12,519,847,261.49 | 42.1x | -76.9x | 15.1x |
| Thu, 26 Jun 2025 | HK$751.6b | HK$62.2b | -HK$12,094,986,236.40 | 31.9x | -62.1x | 12.1x |
| Sat, 24 May 2025 | HK$613.9b | HK$62.1b | -HK$11,737,111,197.29 | 31.2x | -52.3x | 9.9x |
| Mon, 21 Apr 2025 | HK$526.5b | HK$60.3b | -HK$12,128,398,128.16 | 28.6x | -43.4x | 8.7x |
| Wed, 19 Mar 2025 | HK$468.6b | HK$52.7b | -HK$16,880,301,337.51 | 23x | -27.8x | 8.9x |
| Fri, 14 Feb 2025 | HK$367.4b | HK$52.0b | -HK$17,282,300,434.26 | 14x | -21.3x | 7.1x |
| Sun, 12 Jan 2025 | HK$348.6b | HK$51.8b | -HK$17,185,103,623.21 | 11.5x | -20.3x | 6.7x |
| Tue, 10 Dec 2024 | HK$405.3b | HK$52.1b | -HK$17,317,488,088.81 | 11.2x | -23.4x | 7.8x |
| Thu, 07 Nov 2024 | HK$398.9b | HK$52.5b | -HK$17,638,145,578.75 | 11.5x | -22.6x | 7.6x |
| Sat, 05 Oct 2024 | HK$440.5b | HK$52.7b | -HK$18,056,689,472.15 | 12.8x | -24.4x | 8.4x |
| Mon, 02 Sep 2024 | HK$340.4b | HK$52.6b | -HK$19,600,279,846.78 | 11.6x | -17.4x | 6.5x |
| Wed, 31 Jul 2024 | HK$308.4b | HK$49.7b | -HK$19,491,678,475.65 | 11.3x | -15.8x | 6.2x |
| Fri, 28 Jun 2024 | HK$333.2b | HK$49.6b | -HK$19,437,291,027.98 | 12.1x | -17.1x | 6.7x |
| Sun, 26 May 2024 | HK$344.5b | HK$49.8b | -HK$19,517,236,241.02 | 11.7x | -17.7x | 6.9x |
| Tue, 23 Apr 2024 | HK$315.9b | HK$49.5b | -HK$19,910,409,871.62 | 10.8x | -15.9x | 6.4x |
| Thu, 21 Mar 2024 | HK$363.4b | HK$47.8b | -HK$20,968,633,010.96 | 17.5x | -17.3x | 7.6x |
| Sat, 17 Feb 2024 | HK$337.6b | HK$47.2b | -HK$20,382,504,617.35 | 16.3x | -16.6x | 7.2x |
| Mon, 15 Jan 2024 | HK$381.0b | HK$46.9b | -HK$20,252,418,110.00 | 17.7x | -18.8x | 8.1x |
| Wed, 13 Dec 2023 | HK$401.1b | HK$46.8b | -HK$20,200,802,361.00 | 17.9x | -19.9x | 8.6x |
| Fri, 10 Nov 2023 | HK$421.8b | HK$45.2b | -HK$18,930,524,594.00 | 13.5x | -22.3x | 9.3x |
| Sun, 08 Oct 2023 | HK$388.5b | HK$45.0b | -HK$19,137,116,705.00 | 13.8x | -20.3x | 8.6x |
| Tue, 05 Sep 2023 | HK$412.3b | HK$45.1b | -HK$16,929,241,645.00 | 15.1x | -24.4x | 9.1x |
Price to Earnings Ratio
-24.4x
Current Industry PE
- Investors are optimistic on the Hong Kong Biotechs industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 165x which is higher than its 3-year average PE of -69.9x.
- The industry is trading close to its 3-year average PS ratio of 9.9x.
Past Earnings Growth
- Total earnings for the Biotechs industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 33% per year.
- This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | 1.04% | |
| Healthcare | 2.58% | |
| Biotech | 3.12% | |
| Biotech | 3.12% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 1801 Innovent Biologics | HK$107.50 | 5.0% +HK$8.9b | 11.0% | PE130.2x | |
| 9926 Akeso | HK$95.35 | 5.7% +HK$4.7b | -38.8% | PS21.8x | |
| 9995 RemeGen | HK$83.80 | 6.2% +HK$2.7b | -14.6% | PE6.9x | |
| 6938 Suzhou Ribo Life Science | HK$61.80 | 15.7% +HK$1.4b | n/a | PS19.5x | |
| 6915 Jiangxi Institute of Biological Products | HK$20.50 | 28.1% +HK$1.4b | n/a | PE57.2x |